Immunitybio announces fda acceptance of biologics license application for n-803 in bcg-unresponsive non-muscle-invasive bladder cancer carcinoma in situ

Culver city, calif.--(business wire)--the fda accepted for review a biologics license application (bla) from immunitybio, inc. (nasdaq: ibrx), for its antibody cytokine fusion protein as a treatment for patients with bcg-unresponsive non-muscle-invasive bladder cancer carcinoma in situ (cis) with or without ta or t1 disease. immunitybio, a leading clinical-stage immunotherapy company, filed the bla based on positive results from a series of studies of the investigational treatment, including th
IBRX Ratings Summary
IBRX Quant Ranking